Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
Alimera Sciences (Nasdaq: ALIM) announces that its President and CEO, Rick Eiswirth, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alimera Sciences (Nasdaq: ALIM) announces that its President and CEO, Rick Eiswirth, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand from March 9 at 7:00 am ET for 90 days. Investors can register for the conference to view the presentation and request one-on-one meetings with Mr. Eiswirth. Alimera focuses on developing prescription ophthalmology treatments for retinal diseases, addressing significant unmet needs in this area.
Details
News Market Reaction – ALIM
The recorded move for ALIM in the trading session of this news was +8.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Global Life Sciences Conference to be held on March 9-10, 2021.
The presentation will be available on-demand beginning March 9 at 7:00 am ET and be available for 90 days. Investors can view the presentation by registering for the conference here. Mr. Eiswirth will be available for virtual one-on-one meetings with investors on March 9-10, and meeting requests can be made on the conference website once an investor is registered.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.